Edition:
United States

Cytori Therapeutics Inc (CYTX.OQ)

CYTX.OQ on NASDAQ Stock Exchange Capital Market

1.01USD
21 Apr 2017
Change (% chg)

$-0.04 (-3.81%)
Prev Close
$1.05
Open
$1.06
Day's High
$1.06
Day's Low
$1.01
Volume
88,572
Avg. Vol
96,102
52-wk High
$5.41
52-wk Low
$0.99

Latest Key Developments (Source: Significant Developments)

Cytori says public offering of 8.60 mln common shares priced at $1.10 per share
Tuesday, 11 Apr 2017 08:45am EDT 

Cytori Therapeutics Inc : Cytori announces pricing of $9.5m public offering of common stock .Says public offering of 8.60 million common shares priced at $1.10per share.  Full Article

Cytori reports proposed public offering of common stock
Monday, 10 Apr 2017 04:01pm EDT 

Cytori Therapeutics Inc : Cytori announces proposed public offering of common stock .Cytori Therapeutics -intends to use net proceeds for working capital and general corporate purposes, including funding of habeo,ati-0918 development programs.  Full Article

Cytori receives U.S. FDA approval for burn clinical trial related to BARDA contract
Monday, 10 Apr 2017 07:00am EDT 

Cytori Therapeutics Inc - :Cytori receives U.S. FDA approval for burn clinical trial related to BARDA contract.  Full Article

Cytori reports Q4 2016 total revenues $3 million
Thursday, 23 Mar 2017 04:25pm EDT 

Cytori Therapeutics Inc : Cytori reports fourth quarter and full year 2016 business and financial results . Q4 loss per share $0.24 . Q4 earnings per share view $-0.23 -- Thomson Reuters I/B/E/S . Cytori Therapeutics - Expects 2017 operating cash burn to be higher than 2016, primarily due to development of assets acquired from Azaya Therapeutics . Cytori Therapeutics - Q4 2016 total revenues were $3.0 million compared to $3.4 .Cytori Therapeutics Inc - Operating cash burn forecasted to be within a range of $26 million to $29 million for 2017.  Full Article

Azaya Therapeutics Reports 5 pct passive stake in Cytori Therapeutics
Friday, 24 Feb 2017 04:41pm EST 

Cytori Therapeutics Inc :Azaya Therapeutics Inc reports 5 percent passive stake in Cytori Therapeutics as on Feb. 15, 2017.  Full Article

Cytori Therapeutics receives small business designation
Monday, 6 Feb 2017 09:00am EST 

Cytori Therapeutics Inc :Cytori Therapeutics - FDA division of industry consumer education (DICE) has granted small business status to cytori therapeutics for fiscal year 2017.  Full Article

Cytori to acquire proprietary nanoparticle development platform
Thursday, 19 Jan 2017 07:00am EST 

Cytori Therapeutics Inc : Cytori to acquire proprietary nanoparticle development platform to enhance regenerative medicine leadership position . Cytori to acquire proprietary nanoparticle development platform to enhance regenerative medicine leadership position . Cytori Therapeutics - under terms, Cytori's aggregate commercialization milestone payment obligations to Azaya will not exceed $16.25 million . Cytori Therapeutics Inc - under terms of purchase agreement, at closing of acquisition Cytori will issue $2 million in Cytori common stock up front . Cytori Therapeutics Inc - after closing, Cytori, through partners, plans to proceed with Phase 2 clinical studies of ATI-1123 in multiple indications .Cytori Therapeutics - to make additional future payments to azaya based on achievement of certain commercialization milestones, among other things.  Full Article

Cytori to expand Scleroderma focus to its broader hand therapy franchise
Tuesday, 10 Jan 2017 09:30am EST 

Cytori Therapeutics Inc : Cytori to expand scleroderma focus to broader hand therapy franchise under the habeo™ cell therapy brand .Anticipates unblinding of controlled phase 3 clinical trial in patients with scleroderma in mid-2017.  Full Article

Cytori Therapeutics says ADRESU incontinence trial hits 50 pct enrollment milestone
Wednesday, 14 Dec 2016 10:30am EST 

Cytori Therapeutics Inc : Cytori pivotal ADRESU incontinence trial hits 50 pct enrollment milestone .thus far ADRESU therapy has been well-tolerated by study patients, and we currently anticipate full enrollment in mid-2017.  Full Article

Cytori presents scleroderma clinical trial data at the 2016 American College Of Rheumatology annual meeting
Wednesday, 26 Oct 2016 07:00am EDT 

Cytori Therapeutics Inc :Cytori presents scleroderma clinical trial data at the 2016 American College of rheumatology annual meeting.  Full Article

More From Around the Web

BRIEF-Cytori receives U.S. FDA approval for burn clinical trial related to BARDA contract

* Cytori receives U.S. FDA approval for burn clinical trial related to BARDA contract Source text for Eikon: Further company coverage: